“The way we see it, this is an acknowledgement of this effort and also a celebration of science.”
- #wikipedia
- #quote
- #trusted-source
- #apnews.com
- #corroborated

Figure timeline
Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Onc…
Text from Wikipedia, available under CC BY-SA 4.0.
business · German physician and scientist (born 1967) · researcher · entrepreneur · physician · immunologist · academic · university teacher · Privatdozent · board member · also Özlem Türeci, Ozlem Tureci, Ö. Türeci, Ö Türeci, Türeci, Türeci Ö
Born 6 March 1967 · Q92379963
37 published statements · 0 followers
See & hear
3 photos
Media from Wikimedia Commons, hotlinked at the source under its own licence — see each file for author and terms.
Live now
Pulling headlines from trusted outlets — this usually takes a few seconds
Checking the wires…
Feed scan
These are live links, not archived citations — they only join the timeline once a collect run verifies and archives them.
Live pulse
Most recent outstanding titles, awards, and quotes
that’s very difficult to predict in innovative development. But we expect that within only a couple of years, we will also have our vaccines (against) cancer at a place where we can offer them to people.
89%Associated PressSource
“The way we see it, this is an acknowledgement of this effort and also a celebration of science.”
“that’s very difficult to predict in innovative development. But we expect that within only a couple of years, we will also have our vaccines (against) cancer at a place where we can offer them to people.”
Sports Mole: Ozlem Tureci
Published “Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer” in Nature — cited 1,317 times.
Awarded honorary doctor of the University of Antwerp (2022).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Paul Ehrlich and Ludwig Darmstaedter Prize (2022).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded University Teacher of the Year (2022).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Louis-Jeantet Prize for Medicine (2022).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Warren Alpert Foundation Prize (2022).
Text from Wikipedia, available under CC BY-SA 4.0.
Anadolu Ajansi: Scientists Ugur Sahin and Ozlem Tureci receive Princess of Asturias Award
CNBC: BioNTech co-founder Ozlem Tureci on how Covid vaccine will help future drug developments
Doğruluk Payı rated the claim “Uğur Şahin ve Özlem Türeci tıp doktoru değil.” Yanlış.
Shown as reported and rated by a fact checker, not as an established fact.
Awarded Axel Springer Award (2021).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded honorary doctor of University of Cologne in Cologne City Hall (2021).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Knight Commander's Cross of the Order of Merit of the Federal Republic of Germany (2021).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Princess of Asturias Award for Technical and Scientific Research (2021).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded William B. Coley Award (2021).
Text from Wikipedia, available under CC BY-SA 4.0.
Published “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months” in New England Journal of Medicine — cited 1,358 times.
Awarded Catalonia International Prize (2020).
Text from Wikipedia, available under CC BY-SA 4.0.
Awarded Financial Times Person of the Year (2020).
Text from Wikipedia, available under CC BY-SA 4.0.
Published “Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults” in Nature — cited 1,350 times.
Published “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine” in New England Journal of Medicine — cited 14,104 times.
Published “COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses” in Nature — cited 1,790 times.
Published “Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates” in New England Journal of Medicine — cited 2,390 times.
Published “Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer” in Nature — cited 2,276 times.
The company was sold to Astellas Pharma for $1
Text from Wikipedia, available under CC BY-SA 4.0.
Published “Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy” in Nature — cited 1,644 times.
Published “Mutant MHC class II epitopes drive therapeutic immune responses to cancer” in Nature — cited 1,164 times.
Published “mRNA-based therapeutics — developing a new class of drugs” in Nature Reviews Drug Discovery — cited 2,313 times.
Türeci, her husband, and Christoph Huber founded the Mainz-based biotechnology company BioNTech, choosing a name derived from Biopharmaceutical New Technologies
Text from Wikipedia, available under CC BY-SA 4.0.
Co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19
Text from Wikipedia, available under CC BY-SA 4.0.
Career landmark: chief medical officer (2008).
Text from Wikipedia, available under CC BY-SA 4.0.
Completed her habilitation qualification at the Johannes Gutenberg University in Mainz in the field of molecular medicine
Text from Wikipedia, available under CC BY-SA 4.0.
With the foundation of TRON, short for "translational oncology
Text from Wikipedia, available under CC BY-SA 4.0.
Türeci and her future husband founded the company Ganymed Pharmaceuticals
Text from Wikipedia, available under CC BY-SA 4.0.
Born 1967-03-06.
Text from Wikipedia, available under CC BY-SA 4.0.
Türeci is the daughter of Turkish immigrants
Text from Wikipedia, available under CC BY-SA 4.0.
Connections
Family we also track